Zalunfiban dihydrochloride

Cat. No.:	HY-119350B	
Molecular Formula:	$C_{16}H_{20}Cl_2N_8O_2S$	^
Molecular Weight:	459.35	
Target:	Integrin	
Pathway:	Cytoskeleton	
Storage:	4°C, sealed storage, away from moisture	H-CI H-CI
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 6.67 mg/mL (14.52 mM; Need ultrasonic)					
		Mass Solvent 1 mg Concentration	5 mg	10 mg		
	Preparing Stock Solutions 1 mM 2.1770 mL 10.8849 ml 5 mM 0.4354 mL 2.1770 mL	1 mM	2.1770 mL	10.8849 mL	21.7699 mL	
		2.1770 mL	4.3540 mL			
		10 mM	0.2177 mL	1.0885 mL	2.1770 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent of Solubility: ≥ 0.67 n	one by one: 10% DMSO >> 40% PE(ng/mL (1.46 mM); Clear solution	G300 >> 5% Tween-80) >> 45% saline		
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.67 mg/mL (1.46 mM); Clear solution					
	3. Add each solvent o Solubility: ≥ 0.67 n	one by one: 10% DMSO >> 90% cor ng/mL (1.46 mM); Clear solution	n oil			

BIOLOGICAL ACTIV	
Description	Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC ₅₀ =45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI) ^[1] .
IC ₅₀ & Target	IC50: 45 nM (αIIbβ3) ^[1]
In Vivo	Zalunfiban dihydrochloride (1~3.86 mg/kg; s.c.; 24 hours) makes platelet aggregation performed ^[1] . Zalunfiban dihydrochloride (1~3.86 mg/kg; i.m.; 4.5 hours) leads to the onset of high-grade inhibition of platelet aggregation within 15–30 minutes that lasts from ~2 to >4.5 hours in a dose dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.



Product Data Sheet

Animal Model:	Cynomolgus Monkey
Dosage:	1~ 3.86 mg/kg (Pharmacokinetic Analysis)
Administration:	S.c.; 24 hours
Result:	Platelet aggregation was performed.

REFERENCES

[1]. Vootukuri S, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2-3):65-74.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA